Daptomycin dosing in obese patients: analysis of the use of adjusted body weight actual body weight
Background: Food and Drug Administration–approved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations associated with higher weight-based doses required for o...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-01-01
|
| Series: | Therapeutic Advances in Infectious Disease |
| Online Access: | https://doi.org/10.1177/2049936118820230 |